EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis

Lijuan Wang, Xu Chen

Translational Oncology · 2027-01 · 75 · 103110

DOI: 10.1016/j.tranon.2026.103110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2027-01. Verfasst von Lijuan Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University,…. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Medicine Research Program of Zhejiang Province, Taizhou City People's Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has become a mainstay treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance develops in most patients and ultimately compromises durable clinical benefit. Therefore, effective combination strategies to enhance Osimertinib sensitivity and delay or overcome resistance remain an urgent unmet clinical need. METHODS: The antitumor effects of pterostilbene in combination with Osimertinib were evaluated in EGFR-mutant and osimertinib-resistant NSCLC cell lines using CCK-8, colony formation, EdU incorporation, wound healing, and Transwell invasion assays. In vivo efficacy and safety were evaluated in nude mouse xenograft models. To investigate the underlying mechanisms, ferroptosis-related biochemical parameters, protein expression profiles, and transcriptomic profiles were analyzed. The involvement of ferroptosis and FGFR4 signaling was further validated using the ferroptosis inhibitor ferrostatin-1 (Fer-1) and FGFR4 siRNA-mediated knockdown. RESULTS: Pterostilbene markedly potentiated the antitumor efficacy of Osimertinib in vitro and in vivo and restored drug responsiveness in Osimertinib-resistant NSCLC cells. Mechanistically, the combination induced ferroptosis, as indicated by enhanced lipid peroxidation, intracellular Fe2+ accumulation, and reduced expression of key ferroptosis-protective proteins, including GPX4 and xCT. Consistently, pharmacological inhibition of ferroptosis attenuated the antitumor effects of the combination. Furthermore, combined treatment modulated FGFR4-associated ERK/AKT signaling and disrupted redox and iron homeostasis. FGFR4 depletion significantly attenuated ferroptosis induction and reduced the synergistic anticancer effects of the combination, whereas FGFR4 re-expression restored treatment responsiveness, supporting an FGFR4-dependent therapeutic response. CONCLUSION: This study demonstrates that pterostilbene enhances the antitumor efficacy of Osimertinib through the induction of FGFR4-dependent ferroptosis, providing mechanistic insights and suggesting a potential therapeutic strategy to overcome EGFR-TKI resistance in NSCLC.

Schlagwörter

Stichwörter der Autor:innen

FGFR4FerroptosisNon-small cell lung cancerOsimertinibPterostilbene

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University, Taizhou, 318000, Zhejiang, China.
  • Department of Integrated Chinese and Western Medicine, Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University, Taizhou, 318000, Zhejiang, China. Electronic address: 13115760820@16…

Förderung

  • Chinese Medicine Research Program of Zhejiang Province
  • Taizhou City People's Government

Zitieren

APA

Wang, L., & Chen, X. (2027). Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis. Translational Oncology, 75, 103110. https://doi.org/10.1016/j.tranon.2026.103110

Vancouver

Wang L, Chen X. Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis. Translational Oncology. 2027;75:103110. doi:10.1016/j.tranon.2026.103110

BibTeX
@article{Wang2027,
  author = {Wang, Lijuan and Chen, Xu},
  title = {Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis},
  journal = {Translational Oncology},
  year = {2027},
  volume = {75},
  pages = {103110},
  doi = {10.1016/j.tranon.2026.103110}
}
Kostenlos starten →